Robert Langreth Sonja Elmquist
Fight over $1,100 Hepatitis C pills awaits next move by CVS
NEW YORK - Gilead Sciences Inc. may finally be forced to offer a lower price for its $94,500 hepatitis C drug.
The biotechnology company could...









